Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Moodys
Dow
Chubb
US Army
McKinsey
AstraZeneca
Healthtrust

Generated: April 26, 2018

DrugPatentWatch Database Preview

TRI-LEGEST 21 Drug Profile

« Back to Dashboard

When do Tri-legest 21 patents expire, and what generic alternatives are available?

Tri-legest 21 is a drug marketed by Barr and is included in one NDA.

The generic ingredient in TRI-LEGEST 21 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
Summary for TRI-LEGEST 21
Drug patent expirations by year for TRI-LEGEST 21
Synonyms for TRI-LEGEST 21
(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; [(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenant
19-Nor-17-alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, acetate mixed with 19-nor-17-alpha-pregna-1,3,5-(10)-trien-20-yne-3,17-diol
8067-81-0
AC1L1Y7Y
Anovlar 21
Aurovela 1.5/30
Controvlar
Cumorit
Econ 30
ESTROSTEP 21
Etalontin
Ethinyl estradiol mixture with norethindrone acetate
Ethinyl oestradiol mixed with norethisterone acetate
Ethinylestradiol and norethindrone acetate
Gyn-Anovlar
Gynonlar
Gynonlar 21
Hailey Fe 1/20
Junel 1.5/30
Junel 1/20
Lo Loestrin
Lo Loestrin Fe
LOESTRIN 21 1.5/30
LOESTRIN 21 1/20
LOESTRIN FE 1/20
Microgestin
Microgestin 1.5/30
Microgestin 1/20
Minastrin 24 Fe
Neorlest
Norethindrone acetate and ethinyl estradiol
Norethindrone acetate and ethinylestradiol
Norethisterone acetate mixed with ethinyl oestradiol
NORLESTRIN 21 1/50
NORLESTRIN 21 2.5/50
NORLESTRIN 28 1/50
Primodos
SCHEMBL2523461
Sinovula
Taytulla
Trentovlane

US Patents and Regulatory Information for TRI-LEGEST 21

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Barr TRI-LEGEST 21 ethinyl estradiol; norethindrone acetate TABLET;ORAL-21 076405-001 Oct 26, 2007 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
McKesson
Queensland Health
Cerilliant
Argus Health
McKinsey
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.